Aileron Therapeutics Updates Corporate Address in 8-K Filing
Ticker: RNTX · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-update, 8-K
TL;DR
**ALRN filed an 8-K to update its address, no big operational news.**
AI Summary
Aileron Therapeutics, Inc. (ALRN) filed an 8-K on January 29, 2024, to update its corporate information, specifically its business and mailing address to 738 Main Street #398, Waltham, MA 02451. This administrative update ensures the company's public records are current, which is important for investors to have accurate contact information for the company they own or are considering buying stock in, though it doesn't signal a change in operations or financial health.
Why It Matters
This filing is an administrative update, ensuring Aileron Therapeutics' public contact information is current. It doesn't indicate any operational changes or financial performance shifts, but accurate records are fundamental for investor communication.
Risk Assessment
Risk Level: low — This filing is purely administrative, updating contact information, and carries no inherent financial or operational risk.
Analyst Insight
A smart investor would note this as a routine administrative update, confirming the company's current contact details. It provides no new information to alter investment decisions regarding Aileron Therapeutics (ALRN) based on operational or financial performance.
Key Numbers
- $0.001 — par value per share (par value of Aileron Therapeutics' Common Stock)
- 617-995-0900 — business phone number (registrant's telephone number)
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — the registrant filing the 8-K
- ALRN (company) — trading symbol for Aileron Therapeutics, Inc.
- January 29, 2024 (date) — date of earliest event reported and filing date
- 738 Main Street #398, Waltham, MA 02451 (address) — new business and mailing address of Aileron Therapeutics, Inc.
- 001-38130 (number) — Commission File Number for Aileron Therapeutics, Inc.
- The Nasdaq Capital Market (company) — exchange where Aileron Therapeutics' common stock is registered
FAQ
What is the primary purpose of this 8-K filing by Aileron Therapeutics, Inc.?
The primary purpose of this 8-K filing, dated January 29, 2024, is to report an update to Aileron Therapeutics, Inc.'s business and mailing address to 738 Main Street #398, Waltham, MA 02451, as well as other general corporate information.
What is the trading symbol and the exchange where Aileron Therapeutics, Inc. stock is registered?
Aileron Therapeutics, Inc.'s trading symbol is ALRN, and its Common Stock, with a $0.001 par value per share, is registered on The Nasdaq Capital Market.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 29, 2024.
What is the state of incorporation for Aileron Therapeutics, Inc.?
Aileron Therapeutics, Inc. is incorporated in Delaware.
Does this 8-K filing indicate any changes in Aileron Therapeutics, Inc.'s financial performance or operational strategy?
No, this 8-K filing is an administrative update regarding corporate contact information and does not indicate any changes in Aileron Therapeutics, Inc.'s financial performance or operational strategy.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-29 08:14:33
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d103474d8k.htm (8-K) — 24KB
- 0001193125-24-017476.txt ( ) — 140KB
- alrn-20240129.xsd (EX-101.SCH) — 3KB
- alrn-20240129_lab.xml (EX-101.LAB) — 17KB
- alrn-20240129_pre.xml (EX-101.PRE) — 11KB
- d103474d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: January 29, 2024 By: /s/ Manuel C. Alves-Aivado Manuel C. Alves-Aivado, M.D., Ph.D. Chief Executive Officer